TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intraoperative decrease of the heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate of psychostimulant abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year LFS
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral Invasive Recurrence Rate (IIRR)
Endpoint domain: Mortality/survival
Primary endpoint: anti-RBD antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of ultrasonographic features for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in pruritus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) mean and max in lesions detected by PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor to Background Ratio (TBR) of lesions detected by PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year disease free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Dentin erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in disease activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical changes in markers such as tryptase, TLR4, and anti-NR2A antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: acute antipsychotic drug toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' burnout levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Exophthalmos response rates at Week 6 and Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain uptake evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Chemsex behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in sexual self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Partial Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause in-hospital mortality through Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Safety of XP-102
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of XP-102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of XP-102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital outcome measurement completeness
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 6-month outcome measurement completeness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean difference in total volume received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stent diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative ratio of IgG against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: False-positive recall rate
Endpoint domain: Adverse events/effects
Primary endpoint: Positive-predictive values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 60-day ECMO-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unsafe liberation from VV-ECMO
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome of percutaneous balloon pulmonary valvuloplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Status Scale Score (FSS Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of nosocomially infected individuals
Endpoint domain: Adverse events/effects
Primary endpoint: Breastfeeding Assessment Scale (LATCH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on the Swallowing subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Re-intervention free survival
Endpoint domain: Mortality/survival
Primary endpoint: Evolution of the patient's pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sensitivity and specificity of the Active Biopsy Guidance System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary salbutamol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine albumin:creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mood symptoms (post)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mood symptoms (follow-up)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety symptoms (post)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety symptoms (follow-up)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titre (GMT) of SARS-CoV-2 Neutralizing Antibodies (nAb) Against B.1.351 Variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroresponse of SARS-CoV-2 nAb Against the B.1.351 Variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of serum human chorionic gonadotropin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sheehan Disability Scale (SDS) Change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quick Inventory of Depressive Symptoms (QIDS) Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in nicotine boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sensory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60 Day Composite of Thrombotic and Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Weight beating lunge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: GMT of nAb against Delta variant on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of nAb against Omicron variant on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Difference in Scores for APD Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Absence or Presence of Diabetic Retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Severity of Diabetic Retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Absence or Presence of Diabetic Macular Edema (DME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Severity of Diabetic Macular Edema (DME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Baseline VOCs (aldehydes) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of COC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time (AUC0-τ) curve for COC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craniovertebral Angle (CVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants with AEs Leading to Discontinuation of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Starburst Diameter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halos Diameter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glare Disability Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretory IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotator Cuff Integrity on Shoulder MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of outpatients started on empiric treatment for suspected UTI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Adverse Events through 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Limitation of mouth opening (trismus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications from polychemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Berg Balance Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-being perception pre-intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Well-being perception post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the Audiobook App
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Variation of CHIP markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hand dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Boston CTS Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of early radio-induced toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Reader confidence in identifying lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of excellent outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS)-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment-related adverse event (tAE) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with adequate bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central processing of speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Arterial Access Site Closure-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change of trunk control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of trunk equilibrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatments acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Colonic hydrogen per quarter of colonic transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with depression remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reporting solicited local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects reporting solicited systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects reporting Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving serum uric acid levels <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: B-mode ultrasound homogeneity score in salivary glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of EARLY Bladder Cancer recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: disease prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Agreement between frozen sections and two photon microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of workplace violence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with grade 3 or higher CRS
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment limiting toxicities by Day 60
Endpoint domain: Adverse events/effects
Primary endpoint: Number of symptomatic upper and lower respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of flu and cold
Endpoint domain: Adverse events/effects
Primary endpoint: Morbid obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental caries prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility/Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of NST-SPARK
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of NST-SPARK
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Open-ended feedback about the NST-SPARK user experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Arch Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with targeted adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with serious AEs (SAEs) considered related to the Galapagos CAR T-cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who died with causes
Endpoint domain: Mortality/survival
Primary endpoint: Change in pre-bronchodilator 129Xe MRI ventilation defect percent (VDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adoption of evidence-based CV-risk reduction therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postural Assessment Scale for Stroke Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: equipment failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Enamel decalcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atopic Dermatitis Severity Index (ADSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in absolute abundance of S. aureus on target lesion site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rotator cuff healing quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood and tissue analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of muscle synergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of muscle synergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain symmetry index (BSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of neutralizing antibody to the SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects improved or much improved on the GAIS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life level change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shoulder functionality level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection rate of esophageal varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Working load in watt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rest/Max Heart rate in beat/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life (t1/2λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of SIPS-2209-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of SIPS-2209-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactogenicity of LYB004 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of LYB004 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of LYB004 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with a complete response or minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical control of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Local Incidence rates of COVID-19 infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: blood loss during and after cesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of the virtual environment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erythrocyte Reducte Glutathione (GSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Time in Range (TIR) 70-180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary NNAL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: St. George's Respiratory Questionnaire (SGRQ) quality of life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diabetes medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric mean fold rise (GMFR) of serum HI antibody titers against vaccine-homologous H5N8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of seroprotected (SP) participants for HI antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with increased toxicity grading in either Hematological or Biochemical Laboratory Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Hypersensitivity Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Thromboembolic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With VWF or Factor VIII (FVIII) Inhibitor Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-body protein and amino acid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Pressure (both systolic and diastolic blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Saturation Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurodevelopmental outcome at 24+/- 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blindness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant-reported Overall Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of PSA tests ordered per number of clinical encounters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of prostate biopsies performed using NCCN risk levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of prostate biopsy complications
Endpoint domain: Adverse events/effects
Primary endpoint: World Health Organization (WHO) Violence Against Women
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status